Project Name: Bradford Lipid Hub
Project Summary:
The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the population served by the CW Partner.
Planned Milestones:
- Lipid Management pathway/protocol development.
- Development of PCN engagement plan. Collection of baseline data from engaged PCNs, in line with the expected project outcome measurements
- Collection & submission of 3 months clinical activity data.
- Confirmation that recruitment is complete and all recruited project staff are fully trained.
- Collection & submission of 6 months clinical activity data.
- Collection & submission of 9 months clinical activity data.
- Collection & submission of 12 months clinical activity data.
- Development of business case to ongoing utilisation of Lipid Hub piloted in this project.
- Analysis of CWP data, submission of Final CWP Report, Submission of Outcomes Summary.
Expected Benefits:
For the Patient:
- Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
- Enhanced experience and counselling around ASCVD with ongoing management of the condition.
- Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events
- Easier access to lipid management care closer to home in the primary care setting
- The additional capacity will provide additional time and support for lipid management, focusing of patients who may have previously not attended GP appointments or been lost to follow-up. This help to level health inequalities within the practice and, ultimately, in a wider setting.
For the CW Partner:
- Increased proportion of ASCVD patients reviewed by primary care
- Increased proportion of ASCVD patients receiving expert and timely review closer to home
- Reduction in ASCVD referral rates to secondary care
- Increased proportion of patients receiving guideline-directed pharmacotherapy
- Insight into benefits of novel primary care led lipid management clinics and demonstration of benefit via development of business case for substantive funding
- Support aligned to NHS Long Term Plan, CDVPREVENT, and Network Contract DES
- Opportunity to show the impact of the CWP to create lasting change in lipid management within Bradford
For Novartis:
- Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines
- Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with the NHS which addresses the problem of health inequalities
- Ethical, professional, and transparent relationship between Novartis and the NHS
Start Date & Duration: November 2023 for 14 months
UK2312049350
Project Name: Westcliffe ASCVD Lipid Hub
Organisation(s): Westcliffe MC Westcliffe Rd, Shipley BD18 3EE and Novartis Pharmaceuticals UK Limited
Completion Date: July 2025
Outcome Summary:
This project implemented a local pharmacist-led Lipid strategy for the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) who were at high risk of cardiovascular events and who were not achieving lipid levels, as specified in National and/or local guidance, in response to the needs of the population served by the CW Partner. This Project aimed to demonstrate the value of dedicated Pharmacist time into the PCN with a view to achieving substantive future funding.
This project aimed to:
- Identify sub-optimally treated patients who were not achieving recommended targets for lipid management across the PCN who engaged with the service
- Identify patients who have previously not tolerated or refused alternative lipid modification therapies
- Review treatment options in a consultative way with patients
- Counsel and optimise patients where appropriate
Key Project Outcomes Data:
Increase in the number of patients who have attended a review appointment as part of this project: Baseline: 0 End of project: 2000
Increase in the number of patients who have attended a lipid optimisation appointment (if appropriate) as part of this project: Baseline: 0 End of project: 1500
Increase in the number of eligible patients initiated or up-titrated on NICE approved lipid-lowering therapies within duration of project if appropriate:
Baseline: 0 End of project: 1500
Outcomes:
Lipid Management pathway/protocol development - completed
Confirmation that recruitment is complete and all recruited project staff are fully trained. - completed
Development of PCN engagement plan. Collection of baseline data from engaged PCNs, in line with the expected project outcome measurements - completed
Collection & submission of 3,6,9 and 12 months clinical activity data. - completed
Development of business case to ongoing utilisation of Lipid Hub piloted in this project. - completed
Conclusion:
The project team believe this to be a successful project, which is now to be rolled out across Bradford to support the ambition of reducing unwarranted variation in care quality and aligns to strategic imperative of the ICS to reduce health inequalities.
The legacy of the project is the upskilling of the primary care workforce to proactively and confidently manage ASCVD patients in primary care and increased engagement of patient cohorts who may have lost confidence in their local practice, although not all the PCN’s within the CWA engaged with the project, substantive data was collected to demonstrate effectiveness.
FA-11559383 | November 2025